Net Income (Loss) Attributable to Parent in USD of Aldeyra Therapeutics, Inc. from 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Aldeyra Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2010 to Q3 2025.
  • Aldeyra Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$7.69M, a 49.1% increase year-over-year.
  • Aldeyra Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$43.2M, a 3.58% increase year-over-year.
  • Aldeyra Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$55.9M, a 48.8% decline from 2023.
  • Aldeyra Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$37.5M, a 39.5% increase from 2022.
  • Aldeyra Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$62M, a 7.35% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Aldeyra Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$43.2M -$7.69M +$7.42M +49.1% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025
Q2 2025 -$50.6M -$9.77M +$7.08M +42% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 -$57.7M -$9.93M -$1.85M -22.9% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025
Q4 2024 -$55.9M -$15.8M -$11.1M -233% 01 Oct 2024 31 Dec 2024 10-K 28 Feb 2025
Q3 2024 -$44.8M -$15.1M -$6.93M -84.6% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025
Q2 2024 -$37.9M -$16.8M -$7.86M -87.5% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 -$30M -$8.08M +$7.53M +48.2% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025
Q4 2023 -$37.5M -$4.75M +$8.15M +63.2% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2025
Q3 2023 -$45.7M -$8.19M +$6.37M +43.7% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 -$52.1M -$8.99M +$8.79M +49.5% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024
Q1 2023 -$60.9M -$15.6M +$1.17M +6.99% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024
Q4 2022 -$62M -$12.9M +$2.85M +18.1% 01 Oct 2022 31 Dec 2022 10-K 07 Mar 2024
Q3 2022 -$64.9M -$14.6M +$1.24M +7.86% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023
Q2 2022 -$66.1M -$17.8M -$2.84M -19% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023
Q1 2022 -$63.3M -$16.8M -$5.5M -48.7% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023
Q4 2021 -$57.8M -$15.8M -$4.46M -39.5% 01 Oct 2021 31 Dec 2021 10-K 09 Mar 2023
Q3 2021 -$53.3M -$15.8M -$6.92M -78% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 -$46.4M -$14.9M -$7.42M -98.6% 01 Apr 2021 30 Jun 2021 10-Q 05 Aug 2022
Q1 2021 -$39M -$11.3M -$1.42M -14.4% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022
Q4 2020 -$37.6M -$11.3M +$1.87M +14.2% 01 Oct 2020 31 Dec 2020 10-K 17 Mar 2022
Q3 2020 -$39.4M -$8.87M +$9.84M +52.6% 01 Jul 2020 30 Sep 2020 10-Q 28 Oct 2021
Q2 2020 -$49.3M -$7.52M +$5.81M +43.6% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021
Q1 2020 -$55.1M -$9.87M +$5.76M +36.8% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021
Q4 2019 -$60.8M -$13.2M -$2.53M -23.8% 01 Oct 2019 31 Dec 2019 10-K 11 Mar 2021
Q3 2019 -$58.3M -$18.7M -$7.9M -73.1% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020
Q2 2019 -$50.4M -$13.3M -$4.28M -47.3% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020
Q1 2019 -$46.1M -$15.6M -$7.23M -86.1% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020
Q4 2018 -$38.9M -$10.6M -$3.68M -52.9% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2020
Q3 2018 -$35.2M -$10.8M -$5.83M -117% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019
Q2 2018 -$29.4M -$9.05M -$3.74M -70.5% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019
Q1 2018 -$25.6M -$8.4M -$3.31M -64.9% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019
Q4 2017 -$22.3M -$6.95M -$2.3M -49.4% 01 Oct 2017 31 Dec 2017 10-K 08 Mar 2019
Q3 2017 -$20M -$4.99M -$211K -4.42% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018
Q2 2017 -$19.8M -$5.31M -$1.01M -23.4% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018
Q1 2017 -$18.8M -$5.09M -$124K -2.49% 01 Jan 2017 31 Mar 2017 10-Q 15 May 2017
Q4 2016 -$18.7M -$4.65M -$298K -6.85% 01 Oct 2016 31 Dec 2016 10-K 30 Mar 2017
Q3 2016 -$18.4M -$4.78M -$1.41M -41.9% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017
Q2 2016 -$17M -$4.3M -$2.07M -92.8% 01 Apr 2016 30 Jun 2016 10-Q 07 Aug 2017
Q1 2016 -$14.9M -$4.97M -$2.83M -132% 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017
Q4 2015 -$12.1M -$4.36M -$1.91M -78.2% 01 Oct 2015 31 Dec 2015 10-K 30 Mar 2017
Q3 2015 -$10.2M -$3.37M -$1.36M -67.5% 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016
Q2 2015 -$8.82M -$2.23M -$1.1M -96.6% 01 Apr 2015 30 Jun 2015 10-Q 10 Aug 2016
Q1 2015 -$7.73M -$2.14M -$2.54M -632% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016
Q4 2014 -$5.19M -$2.44M -$11.7M -126% 01 Oct 2014 31 Dec 2014 10-K 30 Mar 2016
Q3 2014 $6.55M -$2.01M -$11.3M -122% 01 Jul 2014 30 Sep 2014 10-Q 13 Nov 2015
Q2 2014 $17.9M -$1.14M +$434K +27.6% 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015
Q1 2014 $17.4M $402K +$4.38M 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015
Q4 2013 $13.1M $9.3M 01 Oct 2013 31 Dec 2013 10-K 23 Mar 2015
Q3 2013 $9.31M 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2014
Q2 2013 -$1.57M 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014
Q1 2013 -$3.97M 01 Jan 2013 31 Mar 2013 10-Q 11 Jun 2014

Aldeyra Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$55.9M -$18.3M -48.8% 01 Jan 2024 31 Dec 2024 10-K 28 Feb 2025
2023 -$37.5M +$24.5M +39.5% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2025
2022 -$62M -$4.25M -7.35% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024
2021 -$57.8M -$20.2M -53.9% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023
2020 -$37.6M +$23.3M +38.3% 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2022
2019 -$60.8M -$21.9M -56.4% 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2021
2018 -$38.9M -$16.6M -74.1% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020
2017 -$22.3M -$3.64M -19.5% 01 Jan 2017 31 Dec 2017 10-K 08 Mar 2019
2016 -$18.7M -$6.61M -54.7% 01 Jan 2016 31 Dec 2016 10-K 30 Mar 2017
2015 -$12.1M -$6.9M -133% 01 Jan 2015 31 Dec 2015 10-K 30 Mar 2017
2014 -$5.19M -$18.2M -140% 01 Jan 2014 31 Dec 2014 10-K 30 Mar 2016
2013 $13.1M +$36.1M 01 Jan 2013 31 Dec 2013 10-K 23 Mar 2015
2012 -$23.1M -$20.7M -870% 01 Jan 2012 31 Dec 2012 10-Q 11 Jun 2014
2011 -$2.38M +$1.21M +33.8% 01 Jan 2011 31 Dec 2011 10-Q 11 Jun 2014
2010 -$3.59M 01 Jan 2010 31 Dec 2010 10-Q 11 Jun 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.